These courses are intended for internal hospital staff.

Activity Description:

The grand rounds series on CBCI focuses on the Collection and interpretation of information from peer-reviewed journals, abstracts, and conferences regarding hematopoietic stem cell transplant; CAR-T cell therapy; as well as hematological/immunologic diseases. Scientific methods of currently enrolling clinical trials from Sarah Cannon Research Institute to be understood and discussed. Presentation of materials for discussion. Knowledge exchange and discussion of key issues of Bone Marrow Transplant and Immune effector Cellular therapy. Discussions on how to improve quality outcomes and systemic review of practical policies and procedures. 

Target Audience: 

BMT, Oncology, Radiology, Surgery, Pathology, Radiation Oncology

Learning Objectives:

• Identify the indications and contraindications for new modalities in the prevention, diagnosis, and treatment of CBCI conditions.
• Improve quality outcomes and systemic review of policies and procedures.
• Integrate research techniques related to CBCI condition.

 Moderator:

Richard Nash, MD

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships to disclose with ineligible companies.*

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.

Accreditation:

The HCA Healthcare Continental Division is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Credit Designation:

The HCA Healthcare Continental Division designates this live activity for a maximum of 1.0 AMA PRA Category 1^TM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support:  

This Activity was developed without support from any ineligible company.*The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: 

The HCA Healthcare Continental Division is committed to providing CME that is balanced, objective, and evidenced-based. In accordance with the Accreditation Council for Continuing Medical Education Standards for Integrity and Independence all parties involved in content development are required to disclose all conflicts of interest with ACCME defined ineligible companies. The HCA Healthcare Continental Division has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity. The CME planning committee who are in a position to control the content of this CME Activity, have no relevant financial relationships with ineligible companies to disclose.